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Wehave shown that Sleeping Beauty transposon/transposase can be
harnessed to stably express a CD19-specific chimeric antigen recep-
tor (CD19RCAR) to reprogram T cell specificity to B-cell tumors
independent of human leukocyte antigens (HLA), a technology
that is currently being evaluated clinically (IND#14193). However,
the time required tomanufacture patient-specific T cells to sufficient
numbers ex vivo can be incompatible with the window of opportunity
to treat patients with rapidly-progressing malignancies. An alterna-
tive approach is to prepare allogeneic T cells as third party effector
cells for infusion on demand. However, immune-mediated rejection
by recipient T cells recognizing disparate HLA and graft-versus-
host-disease mediated by the endogenous abT-cell receptor
(TCR) on the infused T cells may compromise this alternative ap-
proach to adoptive immunotherapy. To this end, we investigated
whether HLA and TCR expression can be eliminated in T cells by
designed zinc-finger nucleases (ZFNs). ZFNs are chimeric endonu-
cleases comprised of a zinc finger DNA binding domain designed to
bind a specific DNA sequence fused to the cleavage domain of Fok I
endonuclease. The introduction of a double strand break (DSB) at an
intended target site requires the design of two ZFNs that bind in
a specific spatial orientation to allow dimerization on DNA. Cellular
repair of DSB by error-prone non-homologous end joining results in
the permanent disruption of target gene expression. For an initial
proof-of-concept we designed ZFN pairs targeting the HLA-A lo-
cus. Since only transient expression of ZFNs is needed to perma-
nently disrupt a target gene, we tested the electro-transfer of in
vitro-transcribed ZFN mRNA in primary T cells. We show that ad-
ministration of the mRNA encoding the ZFNs targeting HLA-A re-
sulted in over 40%HLA-A negative primary T cells, which could be
readily enriched by paramagnetic bead separation to obtain a pool of
. 90% HLA-Anull T cells. By using the same approach, we tested
ZFN pairs targeting the TCRa or TCRb locus, resulting in a highly
enriched ab TCRnull cell population (. 90% ab TCRnull). Impor-
tantly, both sets of ZFNs were shown to successfully modify
CD19RCAR T cells, resulting in the efficient elimination of HLA-
A or ab TCR expression from CAR1 T cells which maintain redir-
ected specificity for CD19. These data support the potential for
allogeneic CD19-specific T cells as ‘‘off-the-shelf’’ biologics that
can be infused on demand as ‘‘drugs’’.91
INVERSE CORRELATION BETWEEN BMI AND TIME-TO-ENGRAFTMENT
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Recent studies have shown that adipocytes directly negatively reg-
ulate hematopoietic stem cell (HSC) function. It has also been shown
that visceral adiposity correlates with bone marrow fat content and
therefore increased adipocyte-HSC interaction, which may link
high body mass index (BMI) with increased negative regulation of
HSC function. Clinically, this has significant implications for stem
cell transplant patients, particularly as Americans in general and
the pediatric population in particular becomes more obese.
Many studies investigating the relationship between BMI and
transplant mortality have been done; the results of these studies are
somewhat contradictory. Additionally, interpretation of these stud-ies is complicated by the fact that transplant outcome is an endpoint
significantly downstream of HSC function, and is influenced by
many other factors affected by obesity.We sought to address directly
the issue of HSC function as influenced by adiposity, using the clin-
ical endpoint of engraftment as a proxy measure for hematopoietic
stem and progenitor cell (HSPC) function.
We performed an analysis of BMI and time to engraftment (TTE)
in all patients transplanted at our institution over a two-year interval.
We analyzed data separately from allogeneic bonemarrow recipients
and autologous peripheral blood stem cell recipients. Only data from
the first transplant was analyzed when a subject hadmultiple HSCTs
performed. Linear regression was used to evaluate the relationship
between BMI and TTE. Sixty-one patients had an allogeneic bone
marrow transplant (29 MRD and 32 MURD) and 33 patients had
an autologous HSCT during the study period. There was an inverse
correlation between BMI and TTE in the allogeneic group (r 5
-0.2971, p 5 0.02). BMI did not correlate with TTE in the autolo-
gous HSCT group. BMI also did not correlate with overall survival
in either the autologous or the allogeneic group. Importantly, graft
cell dose did not correlate with TTE in either population.
The negative correlation between BMI and time to engraftment
was unexpected and may be the result of proliferative effects of adi-
pocytes on more mature hematopoietic progenitors. To assess this
possibility in a more controlled setting, we have undertaken an anal-
ysis of HSC and MPP frequency and function by performing mye-
loablative transplants in a murine diet-induced obesity (DIO)
model.STEM CELL BIOLOGY
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Upon transplantation, hematopoietic stem cells (HSCs) home to
specialized bone marrow niches, self-renew and differentiate and
create new, complete hematolymphoid systems. Unfortunately
HSCT/BMT has been limited in part due the toxic conditioning
regimens, such as irradiation and chemotherapy, deemed necessary
forHSC engraftment.We have previously shown that one important
barrier toHSC engraftment is availability of HSCniche space. In the
absence of pre-transplant conditioning, 99% of HSC niches are oc-
cupied with host HSCs and donor HSC engraftment under these
conditions is minimal. We have shown in mouse models, that elim-
ination of host mouse HSCs using anti-mouse-ckit monoclonal an-
tibody ACK2 allows for 90% donor HSC engraftment with
minimal toxicity in immunodeficient animals, which is sufficient to
cure most hematolymphoid disorders.
We examined the effects of SCF-signaling in human HSCs using
various monoclonal antibodies and verified that anti-human-ckit
monoclonal antibody SR-1 uniquely inhibits SCF binding. We cul-
tured purified human BM HSC and CB HSC (CD341CD38-
CD901CD45RA-Lin-) with SR-1 or 4F7 (a non-active anti-hu-
man-ckit clone) and show that SR-1 uniquely inhibits human HSC
proliferation in vitro. Interestingly, SR-1 did not induce human
HSC cell death via apoptosis, but rather shifted the differentiation
profile and increased Glycophorin A1 and CD411 cells (RBC and
platelets respectively), and decreased output of CD14, CD13, and
CD33 cells (macrophages/myeloid cells).
To examine the depleting capability of SR-1 in vivo, robust hu-
man-mouse hematopoietic chimeras were generated using newborn
NOD/SCID/IL-2Rg null mice IV transplanted with 1000 human
CBHSC post 100cGy. By BM aspirate, average pre-treatment base-
line total human bone marrow engraftment (%hCD45) was 58.6%,
and myeloid chimerism (%hCD13/33) was 25.4%. The mice were
then treated IV with 500ug of SR-1 every other day for 1 week.
Human total and myeloid engraftment 8 weeks post treatment de-
creased by 92.4% and 96.9% respectively, most likely due to deple-
tion of human HSCs that maintain these populations. The
remaining persistent human cells in these animals were primarily
